iBio (IBIO) Company Report

iBio, Inc. announced a private placement financing expected to generate approximately $26 million in gross proceeds before fees and expenses.
The company is selling an aggregate of 11,061,738 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $2.35 per share (or $2.349 per pre-funded warrant).
The financing was led by Frazier Life Sciences and included participation from other existing healthcare-focused institutional investors.
iBio intends to use the net proceeds to advance its preclinical cardiometabolic programs, including IBIO-610, IBIO-600, and the myostatin and activin A bispecific programs, and to progress other preclinical pipeline assets.
This financing is expected to extend iBio's cash runway into calendar 2028.

Jan 12, 2026, 10:29 PM

8-K

iBio Announces $26 Million Private Placement

IBIO

New Projects/Investments

iBio, Inc. (NASDAQ:IBIO) announced a private placement (PIPE) financing with existing healthcare-focused, high-quality institutional investors, led by Frazier Life Sciences, expected to result in approximately $26 million in gross proceeds.
The company plans to use the net proceeds to advance its preclinical cardiometabolic programs, including IBIO-610, IBIO-600, and the myostatin and activin A bispecific programs, as well as other preclinical pipeline assets.
This financing is projected to extend iBio’s cash runway into calendar 2028.
iBio is selling an aggregate of 11,061,738 shares of common stock (or pre-funded warrants) at a purchase price of $2.35 per share (or $2.349 per pre-funded warrant).

Jan 9, 2026, 12:00 PM

Press Release

IBIO Discusses Obesity Pipeline, Capital Strategy, and Upcoming Milestones

IBIO

New Projects/Investments

Guidance Update

iBio is an antibody discovery and therapeutics company focused on obesity and cardiometabolic diseases, utilizing a generative AI-integrated platform to develop differentiated molecules.
Its lead program, iBio-610 (long-acting Activin E antibody), has a predicted human half-life of up to 100 days and is anticipated to file for an IND equivalent in Australia by the end of 2026, with the first patient in 2027.
The company's current financing extends its cash runway into Q2 calendar year 2027, with an additional $25 million from warrants tied to IND equivalent acceptance potentially extending it through calendar year 2027.
A significant near-term milestone is the IBIO-600 (anti-myostatin) molecule entering the clinic, with an anticipated filing by end of Q1/beginning of Q2 next year and first patient dose in H1 next year.

Dec 4, 2025, 1:45 PM

Transcript

iBio Updates on Obesity Pipeline, Clinical Timelines, and Financial Strategy

IBIO

New Projects/Investments

Guidance Update

iBio is an antibody discovery and therapeutics company focused on obesity and cardiometabolic diseases, with its lead program, IBIO-610 (long-acting Activin E antibody), predicted to have an extended half-life of up to 100 days in humans based on non-human primate data.
The company anticipates filing for an IND equivalent in Australia for IBIO-610 by the end of 2026, with the first patient in 2027.
IBIO-600 (long-acting anti-myostatin molecule) is expected to enter the clinic by the first half of 2026, marking the first clinical asset from their platform.
iBio's current financing provides cash into Q2 calendar year 2027, with an additional $25 million from warrants tied to IND equivalent acceptance in 2026, potentially extending the runway through calendar year 2027.
The company is pursuing a dual regulatory path for clinical trials, starting with Australia for quicker acceptance and tax benefits, while also preparing for a US IND filing.

Dec 4, 2025, 1:45 PM

Transcript

iBio Updates on Obesity Pipeline, Clinical Milestones, and Financial Runway

IBIO

New Projects/Investments

Guidance Update

iBio is an antibody discovery and therapeutics company primarily focused on obesity and cardiometabolic diseases, with a pipeline designed to address gaps in GLP-1 treatments.
The company's lead program, iBio-610 (Activin E antibody), is anticipated to file for an IND equivalent in Australia by the end of 2026, with the first patient expected in 2027.
The iBio-600 (anti-myostatin molecule) is projected to enter the clinic in the first half of 2026, following an anticipated filing at the end of Q1 or beginning of Q2 2026.
iBio's current financing provides a cash runway into Q2 calendar year 2027, supported by a recent $100 million raise.
The company is actively seeking partnerships for its myostatin program, believing that de-risking milestones, such as the Australian IND equivalent acceptance in 2026, could facilitate actionable dialogues.

Dec 4, 2025, 1:45 PM

Transcript

iBio, Inc. Announces Q1 Fiscal Year 2026 Financial Results and Corporate Updates

IBIO

Earnings

Guidance Update

New Projects/Investments

iBio, Inc. reported revenue of $0.1 million for the three months ended September 30, 2025, compared to no revenue in the prior year period, and a net loss of $(5.720) million. Research and Development expenses increased to $3.6 million for the quarter, up from $1.3 million in the prior year.
The company strengthened its cash position to $49.6 million as of September 30, 2025, after closing a $50 million underwritten public offering with potential for up to $100 million in total gross proceeds upon full exercise of common warrants. This is anticipated to support operations into the fourth quarter of fiscal year 2027.
iBio presented non-human primate data for its IBIO-610 Activin E antibody, suggesting a predicted human half-life consistent with dosing as infrequent as twice per year for obesity treatment.
iBio regained compliance with Nasdaq Listing Rule 5550(a)(2) on November 4, 2025.

Nov 12, 2025, 9:05 PM

8-K

iBio Reports Q1 Fiscal Year 2026 Financial Results and Corporate Updates

IBIO

Earnings

Delisting/Listing Issues

New Projects/Investments

iBio reported $0.1 million in revenue for the first fiscal quarter ended September 30, 2025, with Research and Development expenses increasing to $3.6 million for the period.
The company's cash, cash equivalents, and investments in debt securities totaled $49.6 million as of September 30, 2025, which is expected to support operations into the fourth quarter of fiscal year 2027.
This strengthened cash position follows the closing of a $50 million underwritten public offering, with the potential for an additional $50 million in gross proceeds upon full exercise of common warrants.
iBio presented new non-human primate data for its IBIO-610 Activin E antibody, suggesting a predicted human half-life that could enable dosing as infrequent as twice per year for obesity treatment.
The company also regained compliance with Nasdaq Listing Rule 5550(a)(2) on November 4, 2025.

Nov 12, 2025, 9:01 PM

Press Release

IBIO Discusses Obesity Pipeline and Financial Strategy

IBIO

New Projects/Investments

Guidance Update

IBIO, led by CEO Martin and CFO Duran since January 2023, pivoted in 2022 by acquiring assets from Rubrik Therapeutics to discover hard-to-drug antibodies, focusing on obesity treatments.
The company's pipeline includes an Activin E antibody (highest priority), which is in IND-enabling studies with a goal to file for an IND equivalent in Australia by the end of 2026 and first patient dose in H1 2027.
The myostatin program (iBio 600) is expected to complete tox studies by Q1 2026 and file in Australia in Q2 2026.
IBIO raised $50 million upfront in August, providing a cash runway through Q1 2027, and is actively seeking a partner for its myostatin program.

Nov 10, 2025, 1:30 PM

Transcript

iBio Provides Update on Obesity Pipeline and Financials

IBIO

New Projects/Investments

Guidance Update

Debt Issuance

iBio recently secured $1 million upfront and $52.5 million in commercial milestones from the sale of a PD-1 agonist to Otsuka, following a research agreement with Eli Lilly and an obesity collaboration with AstroBio.
The company is developing a portfolio of next-generation obesity treatments, including Activin E (iBio 610), myostatin (iBio 600), and Amylin programs, designed to address unmet medical needs and complement existing GLP-1 therapies.
Upcoming catalysts include non-human primate data for Activin E in Q1 2026, with an Australian IND filing targeted for end of 2026 and first patient dose in H1 2027. The myostatin program is expected to file in Australia in Q2 2026.
iBio raised $50 million upfront in August (2025) and projects a cash runway through Q1 2027; an additional $50 million is potentially available via warrants triggered by IND acceptance.

Nov 10, 2025, 1:30 PM

Transcript

iBio Provides Update on Obesity Pipeline and Financial Position at Healthcare Conference

IBIO

New Projects/Investments

Guidance Update

iBio secured $1 million upfront and potential $52.5 million in commercial milestones from Otsuka for a PD-1 agonist, and initiated a collaboration with AstroBio for obesity targets.
The company's lead obesity program, an Activin E antibody, is anticipated to release non-human primate data in Q1 2026, with an IND filing in Australia planned for late 2026 and first patient dosing in H1 2027.
iBio's iBio 600 (myostatin) program is expected to complete toxicology studies by Q1 2026 and file an IND in Australia in Q2 2026.
iBio raised $50 million upfront in August 2025, providing a cash runway through Q1 2027, with potential to extend through 2027 upon exercise of additional warrants tied to IND acceptance.